Expand HCWB Menu
HCWB MENU

HCWB Latest Press Releases

-- August 14, 2026 --

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results Globe Newswire 3:15 PM

-- July 29, 2026 --

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering Globe Newswire 9:06 AM

-- July 23, 2026 --

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027 Globe Newswire 8:00 AM

-- June 30, 2026 --

HCW Biologics Regained Compliance with Bid Price Rule Per Nasdaq Compliance Letter Globe Newswire 8:25 AM

-- June 26, 2026 --

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026 Globe Newswire 8:55 AM

-- June 16, 2026 --

HCW Biologics Announces Positive Results for Preliminary Human Data Readout for Phase 1 Clinical Trial Evaluating IL-2 Based Fusion Immunotherapeutic, HCW9302 Monotherapy, in Alopecia Areata Globe Newswire 7:00 AM

-- May 27, 2026 --

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen Globe Newswire 7:45 AM

-- May 22, 2026 --

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement Globe Newswire 4:02 PM

-- May 21, 2026 --

HCW Biologics Inc. Announces Pricing of Approximately $4.0 Million Private Placement Offering At-the-Market Under Nasdaq Rules Globe Newswire 9:53 AM

-- May 15, 2026 --

Biologics Market Momentum Accelerates Across Healthcare, AI, And Global Medical Tourism Globe Newswire 10:14 AM

-- May 14, 2026 --

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results Globe Newswire 4:25 PM
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies Globe Newswire 7:30 AM

-- April 30, 2026 --

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum Globe Newswire 4:20 PM

-- April 27, 2026 --

HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors Globe Newswire 7:30 AM

-- March 31, 2026 --

HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results Globe Newswire 5:05 PM

-- March 17, 2026 --

HCW Biologics Closes Exclusive Worldwide License for HCW11-006 - A High Potential Fusion Immunotherapeutic Globe Newswire 7:50 AM

-- March 16, 2026 --

HCW Biologics Announces Positive Research Results for CAR-T Cell Therapy Manufactured Utilizing Its Commercial-Ready Proprietary Compound, HCW9206, Published in Science Advances Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes